This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (11)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Transplantation  • Kidney Transplantation  • Diabetes Mellitus  • Alert me on articles by topic  Social Bookmarking   What's this?

Bryan N. Becker, MD; Sarah H. Rush, MSW; Dawn M. Dykstra, BA; Yolanda T. Becker, MD; Friedrich K. Port, MD, MS

Arch Intern Med. 2006;166:44-48.

Background  Preemptive kidney transplantation (PreKT) before initiation of chronic dialysis has been examined recently with favorable results as the most effective treatment for kidney failure. Given that few of these studies are disease specific, the present analyses investigated the outcomes of PreKT by transplantation option and diabetes type.

Methods  The impact of PreKT on posttransplantation mortality and graft failure was examined in 23 238 adults with type 1 and type 2 diabetes mellitus (DM), receiving either living or deceased donor kidneys or undergoing simultaneous pancreas-kidney (SPK) transplantation between January 1, 1997, and December 31, 2002.

Results  The PreKTs were provided to 14.4% of patients with type 1 DM and 6.7% of patients with type 2 DM. Cox regression models were used to estimate the effect of PreKT on the adjusted risk ratio (RR) of graft failure and mortality. After adjusting for multiple factors, PreKT in this era was associated with lower RR of mortality only among type 1 and type 2 diabetic recipients of transplants from living donors and SPK transplant recipients with type 1 DM (RR, 0.50-0.65; P<.007 for each). The effect on graft failure was less pronounced, significant only for preemptive SPK transplant recipients (RR, 0.79; P = .01 vs nonpreemptive SPK transplant recipients).

Conclusions  These analyses suggest that PreKT has significant benefits for subsets of patients with types 1 and 2 DM and end-stage renal disease. It also suggests a time trend toward less benefit from preemptive transplants from deceased donors in more recent years compared with the early 1990s. This observation and the discrepancies between RR of graft loss and RR of mortality deserve further study.

Author Affiliations: Departments of Medicine (Dr B. N. Becker) and Surgery (Dr Y. T. Becker), University of Wisconsin–Madison; and Scientific Registry of Transplant Recipients/University Renal Research and Education Association, Ann Arbor, Mich (Mss Rush and Dykstra and Dr Port).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Organ Markets and the Ends of Medicine
Davis and Crowe
J Med Philos 2009;34:586-605.
ABSTRACT | FULL TEXT  

Living Donor Kidney Versus Simultaneous Pancreas-Kidney Transplant in Type I Diabetics: An Analysis of the OPTN/UNOS Database
Young et al.
CJASN 2009;4:845-852.
ABSTRACT | FULL TEXT  

A Survey of Nephrologists' Views on Preemptive Transplantation
Pradel et al.
CJASN 2008;3:1837-1845.
ABSTRACT | FULL TEXT  

Kidney Transplantation as Primary Therapy for End-Stage Renal Disease: A National Kidney Foundation/Kidney Disease Outcomes Quality Initiative (NKF/KDOQITM) Conference
Abecassis et al.
CJASN 2008;3:471-480.
ABSTRACT | FULL TEXT